Treatment of adult short bowel syndrome patients with teduglutide

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 2, 2012, Pages 235-243

  Nørholk, Lærke Marijke ^b   Holst, Jens Juul ^b   Jeppesen, Palle Bekker ^a  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Home parenteral nutrition; Intestinal failure; Short bowel syndrome; Teduglutide

Indexed keywords

CODEINE; GATTEX; GLUCAGON LIKE PEPTIDE 2; LOPERAMIDE; PLACEBO; PROTON PUMP INHIBITOR; REVESTIVE; TEDUGLUTIDE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; CATHETER COMPLICATION; CATHETER INFECTION; DEHYDRATION; DIARRHEA; DIETARY INTAKE; DOSE RESPONSE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FEVER; FLUID INTAKE; HEADACHE; HUMAN; INTESTINE FUNCTION; JEJUNOSTOMY; LEG EDEMA; NAUSEA; PARENTERAL NUTRITION; REVIEW; RHINOPHARYNGITIS; SEPSIS; SHORT BOWEL SYNDROME; SMALL INTESTINE OBSTRUCTION; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

GASTROINTESTINAL AGENTS; GLUCAGON-LIKE PEPTIDE 2; HUMANS; PEPTIDES; SHORT BOWEL SYNDROME;

EID: 84855881643     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.644787     Document Type: Review

References (57)

1. Messing B, Pigot F, Rongier M, et al. Intestinal absorption of free oral hyperalimentation in the very short bowel syndrome. Gastroenterology 1991;13:1502-8
2. Jeppesen PB, Mortensen PB. Intestinal failure defined by measurements of intestinal energy and wet weight absorption. Gut 2000;46:701-6 (Pubitemid 30305789)
3. Fleming CR, Remington M. Intestinal failure. In: Hill GL, editor. Nutrition and the surgical patient. Churchill Livingstone; New York: 1981. p. 219-35
4. O'Keefe SJ, Buchman AL, Fishbein TM, et al. Short bowel syndrome and intestinal failure: consensus definitions and overview. Clin Gastroenterol Hepatol 2006;4:6-10 (Pubitemid 43129518)
5. Buchman AL, Scolapio J, Fryer J. AGA technical review on short bowel syndrome and intestinal transplantation. Gastroenterology 2003;124:1111-34 (Pubitemid 36389810)
6. Nightingale JM, Lennard Jones JE. The short bowel syndrome: what's new and old? Dig Dis 1993;11:12-31
7. Messing B, Crenn P, Beau P, et al. Long-term survival and parenteral nutrition dependence in adult patients with the short bowel syndrome. Gastroenterology 1999;117:1043-50 (Pubitemid 29512662)
8. Goulet O, Joly F, Corriol O, et al. Some new insights in intestinal failure-associated liver disease. Curr Opin Organ Transplant 2009;14:256-61
9. Lauverjat M, Hadj AA, Vanhems P, et al. Chronic dehydration may impair renal function in patients with chronic intestinal failure on long-term parenteral nutrition. Clin Nutr 2006;25:75-81 (Pubitemid 43263530)
10. Jeppesen PB, Langholz E, Mortensen PB. Quality of life in patients receiving home parenteral nutrition. Gut 1999;44:844-52 (Pubitemid 29244222)
11. Baxter JP, Fayers PM, McKinlay AW. A review of the quality of life of adult patients treated with long-term parenteral nutrition. Clin Nutr 2006;25:543-53 (Pubitemid 44070594)
12. Nordgaard I, Hansen BS, Mortensen PB. Colon as a digestive organ in patients with short bowel. Lancet 1994;343:373-6 (Pubitemid 24049553)
13. Jeppesen PB, Mortensen PB. The influence of a preserved colon on the absorption of medium chain fat in patients with small bowel resection. Gut 1998;43:478-83 (Pubitemid 28462031)
14. Heydorn S, Jeppesen PB, Mortensen PB. Bile acid replacement therapy with cholylsarcosine for short bowel syndrome. Scand J Gastroenterol 1999;34:818-23 (Pubitemid 29434498)
15. Joly F, Dray X, Corcos O, et al. Tube feeding improves intestinal absorption in short bowel syndrome patients. Gastroenterology 2009;136:824-31
16. Nightingale JM, Lennard Jones JE, Walker ER, et al. Oral salt supplements to compensate for jejunostomy losses: comparison of sodium chloride capsules, glucose electrolyte solution, and glucose polymer electrolyte solution. Gut 1992;33:759-61
17. Newton CR. Effect of codeine phosphate, lomotil, and isogel on ileostomy function. Gut 1978;19:377-83 (Pubitemid 8342981)
18. Tytgat GN, Huibregtse K. Loperamide and ileostomy output -placebo-controled double-blind crossover study. Br Med J 1975;2:667-8
19. King RF, Norton T, Hill GL. A double-blind crossover study of the effect of loperamide hydrochloride and codeine phosphate on ileostomy output. Aust NZ J Surg 1982;52:121-4 (Pubitemid 12124660)
20. Cortot A, Fleming CR, Malagelada JR. Improved nutrient absorption after cimetidine in short-bowel syndrome with gastric hypersecretion. N Engl J Med 1979;300:79-80 (Pubitemid 9104314)
21. Jacobsen O, Ladefoged K, Stage JG, et al. Effects of cimetidine on jejunostomy effluents in patients with severe short-bowel syndrome. Scand J Gastroenterol 1986;21:824-8 (Pubitemid 16015069)
22. Jeppesen PB, Staun M, Tjellesen L, et al. Effect of intravenous ranitidine and omeprazole on intestinal absorption of water, sodium, and macronutrients in patients with intestinal resection. Gut 1998;43:763-9 (Pubitemid 28539654)
23. Cooper JC, Williams NS, King RF, et al. Effects of a long-acting somatostatin analogue in patients with severe ileostomy diarrhoea. Br J Surg 1986;73:128-31 (Pubitemid 16107246)
24. Rodrigues CA, Lennard Jones JE, Thompson DG, et al. The effects of octreotide, soy polysaccharide, codeine and loperamide on nutrient, fluid and electrolyte absorption in the short-bowel syndrome. Aliment Pharmacol Ther 1989;3:159-69 (Pubitemid 20121778)
25. Ladefoged K, Christensen KC, Hegnhoj J, et al. Effect of a long acting somatostatin analogue SMS 201-995 on jejunostomy effluents in patients with severe short bowel syndrome. Gut 1989;30:943-9 (Pubitemid 19187935)
26. O'Keefe SJ, Peterson ME, Fleming CR. Octreotide as an adjunct to home parenteral nutrition in the management of permanent end-jejunostomy syndrome. JPEN J Parenter Enteral Nutr 1994;18:26-34
27. Jeppesen PB. Growth factors in short-bowel syndrome patients. Gastroenterol Clin North Am 2007;36:109-21.vii
28. Howard L. Home parenteral nutrition: survival, cost, and quality of life. Gastroenterology 2006;130:S52-9
29. Drucker DJ, Erlich P, Asa SL, et al. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci USA 1996;93:7911-16 (Pubitemid 26277138)
30. Wojdemann M, Wettergren A, Hartmann B, et al. Glucagon-like peptide-2 inhibits centrally induced antral motility in pigs. Scand J Gastroenterol 1998;33:828-32 (Pubitemid 28423636)
31. Wojdemann M, Wettergren A, Hartmann B, et al. Inhibition of sham feeding-stimulated human gastric acid secretion by glucagon-like peptide-2. J Clin Endocrinol Metab 1999;84:2513-17
32. Guan X, Karpen HE, Stephens J, et al. GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow. Gastroenterology 2006;130:150-64 (Pubitemid 43049845)
33. Bremholm L, Hornum M, Henriksen BM, et al. Glucagon-like peptide-2 increases mesenteric blood flow in humans. Scand J Gastroenterol 2009;44:314-19
34. Bremholm L, Hornum M, Andersen UB, et al. The effect of glucagon-like peptide-2 on mesenteric blood flow and cardiac parameters in end-jejunostomy short bowel patients. Regul Pept 2011;168:32-8
35. Cani PD, Possemiers S, Van de WT, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009;58:1091-103
36. Brubaker PL, Izzo A, Hill M, et al. Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. Am J Physiol 1997;272:E1050-8
37. Jeppesen PB, Hartmann B, Thulesen J, et al. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology 2001;120:806-15 (Pubitemid 32193176)
38. Jeppesen PB, Lund P, Gottschalck IB, et al. Short bowel patients treated for two years with glucagon-like peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function. Gastroenterol Res Pract 2009;2009:616054
39. Ivory CP, Wallace LE, McCafferty DM, et al. Interleukin-10-independent anti-inflammatory actions of glucagon-like peptide 2. Am J Physiol Gastrointest Liver Physiol 2008;295:G1202-10
40. Sigalet DL, Wallace LE, Holst JJ, et al. Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2. Am J Physiol Gastrointest Liver Physiol 2007;293:G211-21
41. Henriksen DB, Alexandersen P, Hartmann B, et al. Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. Bone 2009;45:833-42
42. Munroe DG, Gupta AK, Kooshesh F, et al. Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc Natl Acad Sci USA 1999;96:1569-73 (Pubitemid 29098492)
43. Dube PE, Brubaker PL. Frontiers in glucagon-like peptide-2: multiple actions, multiple mediators. Am J Physiol Endocrinol Metab 2007;293:E460-5
44. Yusta B, Huang L, Munroe D, et al. Enteroendocrine localization of GLP-2 receptor expression in humans and rodents. Gastroenterology 2000;119:744-55
45. Bjerknes M, Cheng H. Modulation of specific intestinal epithelial progenitors by enteric neurons. Proc Natl Acad Sci USA 2001;98:12497-502 (Pubitemid 33019974)
46. Orskov C, Hartmann B, Poulsen SS, et al. GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors. Regul Pept 2005;124:105-12 (Pubitemid 39488347)
47. Bahrami J, Yusta B, Drucker DJ. ErbB activity links the glucagon-like peptide-2 receptor to refeeding-induced adaptation in the murine small bowel. Gastroenterology 2010;138:2447-56
48. Marier JF, Beliveau M, Mouksassi MS, et al. Pharmacokinetics, safety, and tolerability of teduglutide, a glucagon-like peptide-2 (GLP-2) analog, following multiple ascending subcutaneous administrations in healthy subjects. J Clin Pharmacol 2008;48:1289-99
49. Marier JF, Mouksassi MS, Gosselin NH, et al. Population pharmacokinetics of teduglutide following repeated subcutaneous administrations in healthy participants and in patients with short bowel syndrome and Crohn's disease. J Clin Pharmacol 2010;50:36-49
50. Jeppesen PB, Sanguinetti EL, Buchman A, et al. Teduglutide (ALX- 0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut 2005;54:1224-31 (Pubitemid 41192479)
51. Jeppesen PB, Gilroy R, Pertkiewicz M, et al. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut 2011;60:902-14
52. Jeppesen PB, Hartmann B, Hansen BS, et al. Impaired meal stimulated glucagon-like peptide 2 response in ileal resected short bowel patients with intestinal failure. Gut 1999;45:559-63 (Pubitemid 29447825)
53. Jeppesen PB, Hartmann B, Thulesen J, et al. Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon. Gut 2000;47:370-6
54. Compher C, Gilroy R, Pertkiewicz M, et al. Maintenance of parenteral nutrition volume reduction, without weight loss, after stopping teduglutide in a subset of patients with short bowel syndrome. JPEN J Parenter Enteral Nutr 2011;35:603-9
55. Thulesen J, Hartmann B, Hare KJ, et al. Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice. Gut 2004;53:1145-50 (Pubitemid 38961969)
56. Takeda Pharmaceuticals International Media homepage. Available from: http://www.nycomed.com/media/news-releases/2011/nycomed-submits-european- marketing-authorisation-application-for-teduglutide- -revestive/[last access December 22 2011]
57. Drug Information Online. Available from: http://www.drugs.com/clinical- trials/gattex-teduglutide-shown-reduce- parenteral-support-volume-patients- adult- short-bowel-syndrome-11724.html [last access December 22 2011]